of receipt; the specimens were then stored at -20°C. The GGT assays were made within two months. GGT is stable in serum at -18°C for this period (Rosalki et al., 1970) .
Alkaline phosphatase activity was measured by the method of Kind and King (1954) on a Technicon AutoAnalyzer, Mark II. The normal range is 20-100 iu/l for adults and it was determined on heparinised plasma samples from 220 blood donors. The NTP was measured by the method of Persijn et al. (1968) using the British Drug Houses clinical assay set. The normal range is given as 3'5 to 11 iu/I. The GGT was measured by the method of Szasz (1969) using the Boehringer test combination (catalogue number 15885). The normal range for this method is given as 6 to 28 iu/I for men and 4 to 18 iu/l for women. ALP isoenzymes were separated by two electrophoretic techniques, using either 1 % agarose gel or cellogel as a support medium. Sodium barbitone (8'4 gfl) buffer was used in both methods. Agarose In this laboratory plasma ALP estimations are per-electrophoresis was carried out for 12 to 15 minutes formed routinely when liver function tests are at 300 V and 150 rnA and the gel was cooled by requested. The liver function tests are also carried covering with petroleum spirit (b.p. 30 to 40°C) out when only a plasma ALP test is requested.
through which nitrogen was bubbled. Electro-All plasma samples received from non-pregnant phoresis using cellogel was carried out for 40 minadults in which the ALP level was above the normal utes at a constant voltage of 200 V. ALP isoenzymes limit (100 iu/l) and the bilirubin level less than 34 were located by incubation at 37°C for 30 minutes in p,mol/l were analysed for NTP, GGT, and ALP iso-substrate consisting of 19 ml Na2COa/NaHCOa bufenzymes. Samples were stored at +4°C and the fer (pH 10'0,0,5 molfl), 1 ml of magnesium chloride NTP and ALP analyses were made within 48 hours (100 rnmol/l), sodium ,B-naphthyl phosphate (15 mg), 86
and Fast Blue Salt 'R.R' (Edward Gurr Ltd) (20 mg). The mixture was prepared and filtered immediately before use. The agarose gel was incubated in a Petri dish containing substrate. The cellogel was blotted, placed on a glass plate and covered with Whatman 3MM paper saturated with substrate on which was placed another glass plate. Enzyme activity was shown by the development of purple bands. The 'liver' isoenzyme migrated at the front and the 'bone' isoenzyme at the back of the a2-globulins. As there was overlapping of the zones of liver and bone isoenzyme activity, markers were run with each batch as an aid to identification. Bone isoenzyme was considered to be present if there was enzyme activity on the cathode side of the cathodal edge of the liver isoenzyme. The liver marker was plasma obtained from patients with obstructive jaundice and the bone marker was plasma from children with active rickets.
Markers were placed inaliquotsand stored at-20 o e.
There was no loss of activity or alteration in electrophoretic mobility of the markers during a period of three months. Patients' samples with an ALP activity of more than 300 iu/l were diluted in sodium barbitone buffer to have an activity of 250-300 iu/l, This minimised 'trailing' of the liver isoenzyme and made it easier to detect bone isoenzyme. Both electrophoretic methods could detect an ALP activity as low as 30 iu/l. Normal adult plasma contained only a liver ALP isoenzyme. A bone ALP isoenzyme was recorded if it was detected by both the agarose and cellogel methods. The cellogel method is technically easier and is currently used in this laboratory.
After completion of the analyses the patient's notes were perused for the diagnosis which had been made clinically and supported by the results of ancillary investigations. Treatment with drugs at the time of taking the plasma samples was also noted.
Two hundred and sixty cases were studied during a period of three months.
Results
Plasma samples were classified into two groups according to the ALP isoenzyme pattern:
Liver isoenzyme only-189 cases (73 %) Bone and liver isoenzyme-71 cases (27 %) In this series there were no cases with an ALP bone isoenzyme only.
Plasma enzyme activities were divided into the following ranges: N = normal, S = slightly elevated (upper limit of normal to twice the upper limit of normal), M = markedly elevated (greater than twice the upper limit of normal).
LIVER ALKALINE PHOSPHATASE ISOENZYME ONLY
There were 189 cases in this group. The NTP and GGT activities were elevated in 70% and 90% of cases respectively. There were marked elevations of ALP in 30 %, NTP in 38 %, and GGT in 74 %. Of the 114 cases (60%) with liver disease the NTP activity was elevated in 79 % and the GGT activity in 96%. There were 75 cases (40%) without liver disease and the NTP activity was elevated in 55 % and the GGT activity in 82 %. In 10 of the 75 cases both the NTP and GGT levels were normal and the ALP values were between 100 and 125 iu/I.
LIVER AND BONE ALK ALINE PHOSPHATASE ISOENZYME
There were 71 cases in this group. NTP and GGT activities were elevated in 31 (44%) and 46 (65%) of cases respectively (Table 1) . ALP was markedly elevated in 48 %, NTP in 25 % and GGT in 48 %. Table 4 shows the number of patients in each major clinical group with elevated levels of NTP, GGT, and an ALP bone isoenzyme. Two patients with proved secondary carcinoma of the liver had normal plasma NTP and GGT activities and the ALP level was less than 125 iu/I, In the group with malignant disease (39 patients) the plasma activities of NTP and GGT were elevated in 26 and 32 patients respectively. It is possible that some of these had liver involvement. A plasma ALP bone isoenzyme was found in eight of 11 patients with secondary tumours of bone, and five of these had an elevated NTP activity and 10 had an elevated GGT. Again it was not known whether or not the liver was involved. An ALP bone isoenzyme was found in seven of 29 patients with miscellaneous hepatobiliary disease. Before this study these seven patients had had recent biliary obstruction which had been relieved surgically.
Two patients with Paget's disease of bone who did not have an ALP isoenzyme had been diagnosed as having inactive Paget's disease. In one patient with Paget's disease the NTP and GGT levels were elevated. This patient was recovering from jaundice associated with dothiepin administration. An ALP bone isoenzyme was found in 11 of 16 patients with fractured bones and in four of the five patients without an ALP bone isoenzyme the fracture was very small or old and plasma ALP activity was less than 125 iu/l, In seven patients with osteomalacia the NTP and GGT activities were elevated in five and six patients respectively. Two of the latter patients were receiving phenobarbitone. There were six patients with thyrotoxicosis in whom the NTP activity was elevated in three and the GGT in six.
Congestive cardiac failure was present in two of these patients, and in four an ALP bone isoenzyme was found. Table 2 lists the diagnosis and treatment in 21 patients in whom therapy may have been a causative factor of the abnormal biochemical tests.
There were 13 patients in whom a slightly elevated plasma ALP activity (100-125 iu/I) was the only abnormality and the ALP isoenzyme was a liver type. Two of the patients had liver secondary deposits. It is probable that some of the 11 remaining patients were normal as it would be expected that 2'5 % of normal persons would have plasma ALP values greater than the mean plus 2 SD.
Discussion
In this study 185 patients (71 %) had elevated plasma ALP activities; in each case this was in keeping with the clinical diagnosis. However, there were 29 % of patients in whom an elevated plasma ALP activity was unexpected clinically and these patients present diagnostic problems to clinical and laboratory staff. In such patients additional biochemical tests, particularly the plasma GGT activity and an ALP isoenzyme separation, can be helpful in determining the source of the ALP.
When an ALP liver isoenzyme only was found the NTP and GGT activities were elevated in 70 % and 90 %of patients respectively. In patients with hepatobiliary disease the NTP activity was elevated in 79 % and the GGT in 96%. These results are broadly in agreement with those of other workers (Orlowski, 1963; Rutenburg et al., 1963; Aronsen et al., 1965; Belfield and Goldberg, ]969; Rosalki et al., 1970; Lum and Gambino, 1972; Rosalki, 1975) .
Malignant disease comprised the largest group (72, or 28 % of 260 patients). Of these 72 patients, 71 % and 89% had an elevated NTP and GGT respectively. When malignant liver involvement was present the NTP activity was elevated in 83 % and the GGT in 92 % of patients. Boone et al. (1974) believe that plasma GGT activity is more sensitive than the hepatic scintogram in detecting hepatic metastases. The GGT is a more sensitive test of liver disease than the NTP in that it is more often elevated and to a higher degree. Since the GGT test is easier to perform than the NTP it might well replace the latter.
There were 45 patients with an ALP bone isoenzyme and no liver disease. In these patients the NTP and GGT levels were elevated in 27 % and 49% respectively. Subclinical liver disease is a possibility in some of these patients.
Alcohol abuse is a possible cause of liver disease. Rosalki et al, (1970) found alcoholism the commonest cause of liver disease in patients referred for bio-Origin of an elevated plasma alkaline phosphatase activity in non-jaundiced patients chemical estimati ons. The GGT level is elevated in many alcoholics (Spencer-Peet et al., 1972) , and even in persons classified as heavy drinkers (Rosalki and Rau, 1972) . In the present study an accurate history of alcohol consumption was not available but alcohol may well have been responsible for the abnormal results in some patients.
Phenytoin and phenobarbitone are known hepatic microsomal enzyme inducers (Rosalki et al., 1971) . Greenwood et al. (I973) reported a patient with osteomalacia who had been prescribed glutethamide for a long time and who had an increased rate of disappearance of 3R vitaminD3 from the plasma as well as elevated plasma NTP and GGT activities. The administration of drugs should be considered as a possible cause of elevated plasma ALP, NTP, and GGT levels in non-jaundiced patients.
Although there were only six patients with thyrotoxicosis, it is interesting that an ALP bone isoenzyme was found in four and that all six had an elevated GGT activity. Moreover, in thyrotoxicosis, microsomal enzyme induction has been implicated as a cause of decreased plasma levelsof25 OR vitamin D (Velentzas et al., 1977) .
In the group with no clinical liver or bone disease plasma NTP and GGT activities were often elevated (Table 3) . One patient had diabetes mellitus and another had nephrosis. Both of these diseases may be associated with an elevated level of GGT (Rosalki, 1975) . It was not possible to exclude drug treatment in the other cases as hospital notes may well have been incomplete, particularly those relating to treatment prescribed by their own doctors; also excessive alcohol intake or subclinical liver disease was not excluded.
It is recommended that when the plasma ALP activity is elevated in non-pregnant, non-jaundiced adults a plasma GGT activity should be performed, and if this is normal it is probable that the elevated ALP level is of bone origin. If the GGT activity is elevated a simple qualitative estimation of the plasma ALP isoenzyme should be done. Drug therapy, alcohol abuse, and malignant disease should be borne in mind as possible reasons for elevated plasma enzyme activities in patients in whom there is no clinically recognised aetiology.
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